Warning: The NCBI web site requires JavaScript to function. more...
The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis.
Cleator SJ, Powles TJ, Dexter T, Fulford L, Mackay A, Smith IE, Valgeirsson H, Ashworth A, Dowsett M.
Breast Cancer Res. 2006;8(3):R32. Epub 2006 Jun 21.
Related citations
Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A.
Zentralbl Gynakol. 2006 Apr;128(2):76-81.
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance.
Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O'Connell P, Chang JC.
Breast Cancer Res Treat. 2006 Feb;95(3):229-33.
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L.
J Clin Oncol. 2004 Jun 15;22(12):2284-93. Epub 2004 May 10.
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P.
Lancet. 2003 Aug 2;362(9381):362-9.
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ.
J Clin Oncol. 2005 May 20;23(15):3331-42.
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L.
J Clin Oncol. 2006 Sep 10;24(26):4236-44. Epub 2006 Aug 8.
Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy.
Koike Folgueira MA, Brentani H, Carraro DM, De Camargo Barros Filho M, Hirata Katayama ML, Santana de Abreu AP, Mantovani Barbosa E, De Oliveira CT, Patrão DF, Mota LD, Netto MM, Caldeira JR, Brentani MM.
Oncol Rep. 2009 Oct;22(4):805-13.
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer.
Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, Liu ET.
Breast Cancer Res. 2002;4(3):R3. Epub 2002 Mar 20.
Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients.
Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, Katsumata N, Kang YK, Nishio K, Fujiwara Y.
Breast Cancer Res Treat. 2006 Sep;99(1):9-17. Epub 2006 Jun 5.
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S.
J Clin Oncol. 2005 Oct 10;23(29):7265-77. Epub 2005 Sep 6.
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma.
Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L.
Cancer. 2003 Jun 15;97(12):2960-71.
Gene trio signatures as molecular markers to predict response to doxorubicin cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.
Barros Filho MC, Katayama ML, Brentani H, Abreu AP, Barbosa EM, Oliveira CT, Góes JC, Brentani MM, Folgueira MA.
Braz J Med Biol Res. 2010 Dec;43(12):1225-31. Epub 2010 Nov 26.
Pre-treatment haemoglobin levels and the prediction of response to neoadjuvant chemotherapy in breast cancer.
Beresford MJ, Burcombe R, Ah-See ML, Stott D, Makris A.
Clin Oncol (R Coll Radiol). 2006 Aug;18(6):453-8.
Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
Burcombe R, Wilson GD, Dowsett M, Khan I, Richman PI, Daley F, Detre S, Makris A.
Breast Cancer Res. 2006;8(3):R31. Epub 2006 Jun 21.
Gene expression profile associated with response to doxorubicin-based therapy in breast cancer.
Folgueira MA, Carraro DM, Brentani H, Patrão DF, Barbosa EM, Netto MM, Caldeira JR, Katayama ML, Soares FA, Oliveira CT, Reis LF, Kaiano JH, Camargo LP, Vêncio RZ, Snitcovsky IM, Makdissi FB, e Silva PJ, Góes JC, Brentani MM.
Clin Cancer Res. 2005 Oct 15;11(20):7434-43.
Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.
Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L.
Cancer J. 2002 Nov-Dec;8(6):461-8.
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.
Breast Cancer Res. 2008;10(2):R30. Epub 2008 Apr 1.
Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses.
Ellis M, Davis N, Coop A, Liu M, Schumaker L, Lee RY, Srikanchana R, Russell CG, Singh B, Miller WR, Stearns V, Pennanen M, Tsangaris T, Gallagher A, Liu A, Zwart A, Hayes DF, Lippman ME, Wang Y, Clarke R.
Clin Cancer Res. 2002 May;8(5):1155-66.
Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.
Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, Namiki M, Kohri K, Matsushita Y, Fujioka T, Nakamura Y.
Clin Cancer Res. 2005 Apr 1;11(7):2625-36.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on